Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17839407 | 1.00 | NR1H4 (0.54) | NR1H4FABP1 | |
| SCHEMBL17848920 | 1.00 | NR1H4 (0.54) | NR1H4FABP1 | |
| SCHEMBL17839406 | 1.00 | NR1H4 (0.54) | NR1H4FABP1 | |
| SCHEMBL17856090 | 0.93 | NR1H4 (0.58) | NR1H4FABP1 | |
| SCHEMBL17839449 | 0.93 | NR1H4 (0.58) | NR1H4FABP1 | |
| SCHEMBL17839753 | 0.90 | NR1H4 (0.45) | NR1H4 | |
| SCHEMBL17856078 | 0.90 | NR1H4 (0.45) | NR1H4 | |
| SCHEMBL17848923 | 0.90 | NR1H4 (0.45) | NR1H4 | |
| SCHEMBL17839790 | 0.89 | TDP1 (0.46) | NR1H4 | |
| SCHEMBL17839792 | 0.89 | TDP1 (0.46) | NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020231917-A1 | ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2020-11-19 | — | — | WO | disclosed |
| US-20200361920-A1 | ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361920-A1 | ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | SLC10A1, NR1H4, SLC10A2 | NR1H4 2/4885FABP1 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.